quantitative
Analysis v1
39
0
After 3 months of oral semaglutide treatment, 32 people with type 2 diabetes had a 16% lower score on a test for fatty liver disease.
Scientific Claim
In 32 adults with type 2 diabetes, oral semaglutide use over 26 weeks was associated with a 16.2% reduction in Fatty Liver Index (from 61.1 to 51.2) at 3 months.
Original Statement
“FLI, an important laboratory surrogate of fatty liver disease, decreased significantly as early as T3, and this improvement was maintained up to T6 ( Table 3 ).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study is observational with no control group, so causation cannot be established. The use of 'associated with' correctly reflects the evidence.
Evidence from Studies
Supporting (1)
39
Contradicting (0)
0
No contradicting evidence found